Electrocore LLC

NASDAQ ECOR

Data sourced from iex and EODHD
Download Data

Electrocore LLC Price to Sales Ratio (P/S) on June 03, 2024: 2.03

Electrocore LLC Price to Sales Ratio (P/S) is 2.03 on June 03, 2024, a -13.66% change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.
  • Electrocore LLC 52-week high Price to Sales Ratio (P/S) is 3.38 on January 30, 2024, which is 66.76% above the current Price to Sales Ratio (P/S).
  • Electrocore LLC 52-week low Price to Sales Ratio (P/S) is 1.75 on July 27, 2023, which is -13.67% below the current Price to Sales Ratio (P/S).
  • Electrocore LLC average Price to Sales Ratio (P/S) for the last 52 weeks is 2.38.
NASDAQ: ECOR

Electrocore LLC

CEO Mr. Daniel S. Goldberger
IPO Date June 22, 2018
Location United States
Headquarters 200 Forge Way, Rockaway, NJ, United States, 07866
Employees 68
Sector Healthcare
Industry Medical devices
Description

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

StockViz Staff

September 20, 2024

Any question? Send us an email